Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

NBIX Neurocrine Biosciences Inc

138,05

1,52 (1,11%)

Zuletzt aktualisiert: 16:53:36

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/17/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

11/29/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Ingrid Delaet

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Neurocrine Biosciences Charts.

Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Neurocrine Biosciences Charts.

News Neurocrine Biosciences Inc

Form 8-K - Current report
Freitag 20 Dezember 2024 (6 Tage vor) • Edgar (US Regulatory)

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Freitag 20 Dezember 2024 (6 Tage vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 19 Dezember 2024 (7 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 19 Dezember 2024 (7 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 17 Dezember 2024 (1 Woche vor) • Edgar (US Regulatory)

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Samstag 14 Dezember 2024 (2 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 4 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Freitag 29 November 2024 (4 Wochen vor) • Edgar (US Regulatory)

Neurocrine Biosciences to Participate at Investor Conferences in December
Dienstag 26 November 2024 (4 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 12 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 8 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Donnerstag 7 November 2024 (2 Monate vor) • PR Newswire (US)

Weitere Neurocrine Biosciences Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen